GAMMA Investing LLC Boosts Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

GAMMA Investing LLC boosted its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 4,555.0% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,586 shares of the company's stock after purchasing an additional 5,466 shares during the quarter. GAMMA Investing LLC's holdings in Mirum Pharmaceuticals were worth $252,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC bought a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth $413,000. Rhumbline Advisers lifted its stake in Mirum Pharmaceuticals by 2.4% in the fourth quarter. Rhumbline Advisers now owns 53,113 shares of the company's stock worth $2,196,000 after acquiring an additional 1,236 shares during the period. Bank of New York Mellon Corp grew its holdings in Mirum Pharmaceuticals by 8.4% during the 4th quarter. Bank of New York Mellon Corp now owns 124,328 shares of the company's stock worth $5,141,000 after acquiring an additional 9,629 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in Mirum Pharmaceuticals by 100.0% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock worth $30,000 after acquiring an additional 357 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Mirum Pharmaceuticals by 1.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 332,639 shares of the company's stock valued at $13,755,000 after purchasing an additional 4,478 shares during the period.

Mirum Pharmaceuticals Stock Down 1.9%

NASDAQ:MIRM traded down $0.98 during midday trading on Wednesday, reaching $50.13. 272,409 shares of the stock traded hands, compared to its average volume of 474,034. The stock has a market capitalization of $2.48 billion, a PE ratio of -31.14 and a beta of 0.95. Mirum Pharmaceuticals, Inc. has a 12-month low of $32.34 and a 12-month high of $54.23. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.04 and a current ratio of 3.22. The business has a 50-day moving average of $44.77 and a two-hundred day moving average of $45.12.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative return on equity of 33.63% and a negative net margin of 20.39%. The business had revenue of $111.59 million for the quarter, compared to the consensus estimate of $98.47 million. During the same period in the prior year, the firm posted ($0.54) earnings per share. The business's quarterly revenue was up 61.2% on a year-over-year basis. On average, equities analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on MIRM. Raymond James Financial reaffirmed a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research report on Tuesday, May 13th. JMP Securities boosted their price objective on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a research note on Friday, May 9th. HC Wainwright reaffirmed a "buy" rating and set a $73.00 target price on shares of Mirum Pharmaceuticals in a research report on Monday, May 19th. Finally, Robert W. Baird lifted their price target on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a report on Thursday, February 27th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $65.50.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.